Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...

The Trump administration has decided not to go forward with a proposal for Medicare and Medicaid to cover high-demand obesity ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Advances recognized by science’s most lucrative awards include high-energy physics experiments and groundbreaking weight-loss ...

States that do provide coverage have tried to manage costs by putting prescribing limits on the GLP-1s. There’s also some ...

Ozempic and similar semaglutide-based medications have been hailed as miracle drugs. Known as GLP-1 (glucagon-like peptide-1) ...

The Trump administration has decided not to expand Medicare and Medicaid coverage for popular obesity drugs, blocking a Biden ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of ...

The Trump administration rejected a proposed rule to allow Medicare to cover blockbuster obesity drugs for weight loss alone ...

This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.